title: Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Hiroshima
authors.forename: Katsushi
authors.initials: K
authors.lastname: Tajima
authors.forename: Yousuke
authors.initials: Y
authors.lastname: Shiono
authors.forename: Ikuko
authors.initials: I
authors.lastname: Suzuki
authors.forename: Kei
authors.initials: K
authors.lastname: Kouno
authors.forename: Masakazu
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kato
authors.forename: Takeo
authors.initials: T
authors.lastname: Kato
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001201:Ascites / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008224:Lymphoma, Follicular / Q000150:complications / Q000188:drug therapy*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone